Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel .
AKAMPIONApril 12, 2021 GMT
- Company forms international consortium with ProteoGenix SAS and Amsterdam UMC
Schlieren (Zurich Area), Switzerland – April 12, 2021 – ImmunOs Therapeutics AG, a Swiss bio-technology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that is has received public funding from the European Union’s Eurostars-2 Programme and the Swiss Innovation Agency Innosuisse. The funds have been granted for the development of a pioneering HLA-open conformer-specific antibody to treat chronic inflammatory rheumatic diseases. Research will be conducted by a consortium with ProteoGenix SAS (Strasbourg, France) and Amsterdam University Medical Centres (Amsterdam, The Netherlands).
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
T-knife Therapeutics Announces the Appointment of Donald Wuchterl as Senior Vice President and .
AKAMPIONApril 7, 2021 GMT
San Francisco, CA / Berlin, Germany – April 7, 2021 T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing innovative therapeutics for the benefit of solid tumor patients and their families, today announced the appointment of Donald Wuchterl as Senior Vice President and Chief Manufacturing Officer. In this newly appointed role, Mr. Wuchterl will oversee process and analytical development, quality assurance and quality control, and viral vector and cell therapy manufacturing activities.
“I am very pleased to welcome Don to the T-knife team,” stated Thomas M. Soloway, Chief Executive Officer of T-knife. “Don’s proven track-record of building and leading highly functioning cell therapy, biologics and gene therapy manufacturing orga
Share:
Kaiserslautern, Germany, February 22, 2021 – SEQ-IT, a leading molecular services provider, today announced they completed a novel mass spectrometry based rapid test for the detection of 20 of the most relevant SARS-CoV-2 mutations including the UK (B.1.1.7), South African and Brazilian variants. The test panel was developed using Agena Bioscience s MassARRAY® System, a well-established tool used by clinical laboratories worldwide to deliver affordable, highly accurate genomic testing. SEQ-IT has been heavily involved in the COVID-19 pandemic response since its beginning. We strive to consistently adapt and improve our testing services to respond to the dynamically changing needs in this crisis. The MassARRAY® System puts us in the position to quickly and reliably test samples for the most relevant Corona variants, said Dr. Bernhard Thiele, CEO of SEQ-IT.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
T-knife Announces Appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. .
AKAMPIONJanuary 19, 2021 GMT
San Francisco, CA / Berlin, Germany – January 19, 2021 T-knife GmbH, a next-generation adoptive T-cell therapy company leveraging its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, today announced the appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer. Elisa Kieback, T-knife’s co-founder and founding CEO, has assumed the role of Chief Technical Officer.
“We welcome Tom and Camille to T-knife and look forward to their contributions as we continue to build our best-in-class T-cell receptor platform, advance our pipeline of innovative cell therapies, and transition to becoming a clinical-stage company in 2021,” stated Alexander Mayweg, Ph.D